LY2510924 peptide has been compared in preclinical studies with AMD3100, a CXCR4-targeting small molecule inhibitor that is approved by the United States Food and Drug Administration for HSC mobilization in multiple myeloma and non-Hodgkin’s lymphoma patients [25, 26]. This evidence concerns the gene CXCR4 and plasma cell myeloma.